Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore.

ABSTRACT:

Background

CDK4/6 inhibitors have shown promising results for treating advanced breast cancer (ABC) and are routinely used in Singapore. In view of their high costs, it is important to assess their relative value compared to existing standards of care in the local setting.

Aims

This study evaluates the cost-effectiveness of adding ribociclib to goserelin and a nonsteroidal aromatase inhibitor or tamoxifen as initial therapy for premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC in Singapore.

Methods

A partitioned survival model with four health states (progression-free on first-line treatment, progression-free on second-line treatment, progressed disease, and death) was developed from a healthcare sy

SUBMITTER: Loke L 

PROVIDER: S-EPMC7941436 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature